An Open-label, Multicentre Extension Study to Evaluate the Long-Term Safety, Tolerability and Effects of Intravenous AEB1102 in Patients With Arginase I Deficiency Who Previously Received Treatment in Study CAEB1102-101A

Trial Profile

An Open-label, Multicentre Extension Study to Evaluate the Long-Term Safety, Tolerability and Effects of Intravenous AEB1102 in Patients With Arginase I Deficiency Who Previously Received Treatment in Study CAEB1102-101A

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Pegzilarginase (Primary)
  • Indications Hyperargininaemia
  • Focus Adverse reactions
  • Sponsors Aeglea Biotherapeutics
  • Most Recent Events

    • 12 Apr 2018 According to an Aeglea Biotherapeutics media release, data are being presented at the 2018 Annual Clinical Genetics Meeting (April 10-14).
    • 12 Apr 2018 Results (N=2) published in an Aeglea Biotherapeutics Media Release.
    • 13 Mar 2018 According to an Aeglea Biotherapeutics media release, additional updates from the two adult patients in this long-term extension study is expected at the ACMG Annual Clinical Genetics Meeting in April 2018 and in the third quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top